Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

Stock-Split Watch: Are These 2 Top Growth Stocks Next?

Should You Invest in the iShares Biotechnology ETF (IBB)?

Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup

Watch for potential wave of share splits as the average price of S&P 500 stock hits $160, says Strategas

Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA

Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

3 Biotech Stocks to Buy for the Next Bull Run: March 2024

FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

US FDA declines to approve Regeneron's blood cancer therapy

UPDATE 1-US FDA declines to approve Regeneron's blood cancer therapy

Regeneron Provides Update on Biologics License Application for Odronextamab

Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs

Top Research Reports for JPMorgan Chase, Merck & SAP

Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study

UPDATE 1-US appeals court revives Regeneron's antitrust lawsuit against Novartis